{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:44:43Z","timestamp":1793303083488,"version":"4.5.0"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T00:00:00Z","timestamp":1702425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Erythemato\u2010ceruminous otitis externa (ECOE) is frequently seen in dogs affected with an allergic skin disease, with recurrent secondary bacteria and yeast overgrowths (detected on cytological examination).<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The objective of the study was to compare the efficacy and safety of an ear spray containing only hydrocortisone aceponate glucocorticoid diester (HCA) to a control product (CTRL), an approved otic formulation containing prednisolone\u2010miconazole\u2010polymyxin combination, in dogs with ECOE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Animals<\/jats:title><jats:p>In total, 97 and 104 dogs with ECOE were respectively randomly assigned to the tested ear treatment product group (HCA) or the commercially available ear treatment control product group (CTRL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods<\/jats:title><jats:p>Dogs were treated for 7\u201314\u2009days, as needed. At Day (D)0, D7, D14, D28 and D42, Otitis Index Score\u20103, hearing test, pruritus and pain visual analogue scales, and cytological scores were graded. The overall response to treatment also was assessed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All clinical parameters decreased rapidly and in a similar way without any significant difference at any time between treatment groups. A good\u2010to\u2010excellent response to treatment was seen in &gt;90% of dogs of both groups as early as D14. The treatment was considered safe in all dogs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Clinical Relevance<\/jats:title><jats:p>A 7\u2010 to 14\u2010day ear topical application of HCA alone to dogs with ECOE accompanied with bacterial and\/or fungal (yeast) overgrowth was safe and led to no statistical difference in improvement of clinical scores relative to the CTRL combination. Based on these results, it may be necessary to reconsider the routine use of antimicrobial drugs such as antibiotics and antifungals as a first\u2010line treatment for ECOE that is likely to have been caused by an allergic reaction.<\/jats:p><\/jats:sec>","DOI":"10.1111\/vde.13224","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T08:45:37Z","timestamp":1702543537000},"page":"197-206","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Efficacy and safety of a hydrocortisone aceponate\u2010containing ear spray solution in dogs with erythemato\u2010ceruminous otitis externa: A randomised, multicentric, single\u2010blinded, controlled trial"],"prefix":"10.1111","volume":"35","author":[{"given":"Delphine","family":"Rigaut","sequence":"first","affiliation":[{"name":"Virbac SA  Carros France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Briantais","sequence":"additional","affiliation":[{"name":"Virbac SA  Carros France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5328-7792","authenticated-orcid":false,"given":"Pierre","family":"Jasmin","sequence":"additional","affiliation":[{"name":"Virbac SA  Carros France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bidaud","sequence":"additional","affiliation":[{"name":"Virbac SA  Carros France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,12,13]]},"reference":[{"key":"e_1_2_10_2_1","first-page":"243","article-title":"Otitis externa in the dog \u2013 etiology and clinical findings, literature review and retrospective study of 752 cases","volume":"32","author":"Carlotti DN","year":"1997","journal-title":"Prat Med Chir Anim"},{"key":"e_1_2_10_3_1","first-page":"405","article-title":"Prospective study on otitis externa in the adult dog in France","volume":"35","author":"Bensignor E","year":"2000","journal-title":"Prat Med Chir Anim Comp"},{"key":"e_1_2_10_4_1","first-page":"3","article-title":"A prospective study of canine otitis in general practice","volume":"53","author":"Aymeric\u2010Cuingnart E","year":"2018","journal-title":"Rev Vet Clin"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2007.00619.x"},{"key":"e_1_2_10_6_1","article-title":"A review of 200 cases of otitis externa in the dog (abstract)","volume":"14","author":"Paterson S","year":"2003","journal-title":"Vet Derm"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jsap.12813"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2011.01058.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2010.00927.x"},{"key":"e_1_2_10_10_1","article-title":"Can topical hydrocortisone aceponate effectively control allergic otitis externa and reduce the risk of recurrence? A double\u2010blinded, placebo\u2010controlled, prospective study (abstract)","volume":"28","author":"Bergvall KE","year":"2017","journal-title":"Vet Dermatol"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.04.066"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2009.00756.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12163"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2008.00728.x"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01075.x"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12917-018-1627-5"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/vde.12977"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09743.x"},{"key":"e_1_2_10_19_1","article-title":"Interventions to reduce staphylococcus aureus in the management of eczema","volume":"2019","author":"George SM","year":"2019","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.13224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T02:10:36Z","timestamp":1709518236000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.13224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,13]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1111\/vde.13224"],"URL":"https:\/\/doi.org\/10.1111\/vde.13224","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"value":"0959-4493","type":"print"},{"value":"1365-3164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,13]]},"assertion":[{"value":"2022-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-28","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}